Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women (non-childbearing potential) with a diagnosis of Alzheimer's Disease according to the NINCDS-ADRDA clinical criteria.~2. Mild to moderate stage of Alzheimer's disease according to MMSE 18-26 inclusive.~3. Modified Hachinski Ischemic Scale equal to or below 4.~4. Geriatric Depression Scale below or equal 7.~5. If anticholinesterasic treatment had been prescribed, the patient must undergo a 4 week wash out period before the baseline visit (visit 1).~6. If Memantine treatment had been prescribed, the patient must undergo a 4 week wash out period before the baseline visit (visit 1).~Exclusion criteria:~1. Clinical, laboratory or neuroimaging findings consistent with:~* other primary degenerative dementia, (dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)~* other neurodegenerative condition (Parkinson's Disease, amyotrophic lateral sclerosis, etc.)~* cerebrovascular Disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions \> one quarter of the total white matter)~* other central nervous system diseases (severe head trauma, tumors, subdural haematoma or other space occupying processes, etc.)~* seizure disorder~* other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency confirmed by current analyses not older than 1 month, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.) 2. A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder.~  3. Chronic daily drug intake for a time period of ≥ 14 days or expected for ≥ 14 days: ~* antidepressants, benzodiazepines, neuroleptics, major sedatives or other anti-inflammatory drugs including acetylic salicylic acid defined~* antiepileptics~* anticholinergics~* nootropics (including Ginkgo)~* centrally active anti-hypertensive drugs (clonidine, alpha-methyl dopa, guanidine, guanfacine,)~* opioid containing analgesics~* anti-inflammatory agents, cortico-steroids or immunosuppressants~* Cimetidin as gastroprotective drug 4. Severe thrombocytopenia defined as platelet counts \<100.000 per mm3. 5. Coagulation disorders

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Lornoxicam (Type: EXPERIMENTAL): Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).